NASDAQ$GOCO
GoHealth Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
GoHealth's Q2 2024 performance saw a decrease in revenue and submissions, but an improvement in net loss compared to the prior year period.
GoHealth reported a decrease in net revenues to $105.9 million due to a 6% decrease in total submissions. The company experienced a net loss of $59.3 million, an improvement of $10.9 million compared to the prior year period. Despite the revenue decline, GoHealth is intensifying targeted marketing efforts for the upcoming AEP and focusing on technology advancements in AI and automation.
- Net revenues for Q2 2024 were $105.9 million, a decrease of $36.9 million compared to the prior year period.
- Submissions for Q2 2024 totaled 152,394, a 6% decrease compared to the prior year period.
- Net loss for Q2 2024 was $59.3 million, an improvement of $10.9 million compared to the prior year period.
- Adjusted EBITDA for Q2 2024 was negative $12.3 million, a decrease of $13.1 million compared to the prior year period.
Headline financials
Revenue & EPS history
GoHealth · Revenue · Quarterly
$106M
Revenue by segment
GoHealth · $11.9M total across 4 segments · Q1 2026
- Medicare Agency Revenue$9.8M—82.2%
- Other Non-Agency Revenue$1.76M—14.8%
- Medicare Non-Agency Revenue$200K—1.7%
- Other Agency Revenue$155K—1.3%
Forward guidance
GoHealth anticipates growth in Submission volume, revenue, and Adjusted EBITDA for the remainder of 2024. The mix of agency versus non-agency agreements will be a key driver of cash flow from operations performance.
Tailwinds
- Anticipates growth in Submission volume
- Expects increase in revenue
- Projects growth in Adjusted EBITDA
- Strategic focus on agency versus non-agency agreements
- Disciplined execution to achieve goals and deliver long-term value
Headwinds
- Various factors expected to influence the second half of the year
- Decline in net revenues due to decrease in total Submissions
- Decrease in Submissions generated by external GoPartner Solutions agents
- Decrease in Adjusted EBITDA compared to prior year period
- Trailing twelve months positive cash flow from operations decreased compared to prior year period
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2024
-7.7%
Avg return
Earnings day
-9.7%
Avg return
5 days after
-6.6%
Avg return
30 days after
26%
6 / 23 earnings
Positive
+32.2%
Q1 2023
Best reaction
-45.5%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.5% | -23.4% | — | |
| Q3 2025 | -24.4% | -32.0% | -12.8% | |
| Q2 2025 | -9.0% | -7.6% | -23.8% | |
| Q1 2025 | -0.6% | -17.4% | -21.4% | |
| Q4 2024 | -14.4% | -14.9% | -32.8% | |
| Q3 2024 | -6.6% | -0.4% | -15.4% | |
| Q2 2024 | -21.4% | -28.3% | -34.0% | |
| Q1 2024 | -8.0% | -11.1% | +2.2% | |
| Q4 2023 | -13.0% | -25.7% | -27.0% | |
| Q3 2023 | +2.3% | +6.7% | +7.4% | |
| Q2 2023 | +6.8% | +6.3% | -17.2% | |
| Q1 2023 | +32.2% | +44.8% | +99.5% | |
| Q4 2022 | -19.9% | -6.2% | -18.5% | |
| Q3 2022 | -16.7% | -9.4% | +95.3% | |
| Q2 2022 | -31.5% | -43.3% | -57.0% | |
| Q1 2022 | +11.1% | +4.9% | +6.5% | |
| Q4 2021 | +23.7% | +37.7% | -9.8% | |
| Q3 2021 | +1.1% | -4.7% | -18.1% | |
| Q2 2021 | -45.5% | -42.2% | -34.7% | |
| Q1 2021 | -2.7% | -5.6% | -4.0% | |
| Q4 2020 | -14.9% | -16.9% | -4.1% | |
| Q3 2020 | -14.9% | -15.1% | +1.8% | |
| Q2 2020 | -10.5% | -18.5% | -27.1% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro